Crossmark

Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States

Crossref DOI link: https://doi.org/10.1007/s40121-024-01067-1

Published Online: 2024-11-08

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yi, Zinan https://orcid.org/0009-0002-4997-3121
Owusu-Edusei, Kwame

Elbasha, Elamin
Funding

Funding for this research was provided by:

Merck & Co., Inc., Rahway, NJ, USA
License Information

Text and Data Mining valid from 2024-11-08

Version of Record valid from 2024-11-08
More Information

Article History

Received: 21 August 2024

Accepted: 11 October 2024

First Online: 8 November 2024

Declarations

:

: This study was performed by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Zinan Yi, Kwame Owusu-Edusei, and Elamin Elbasha are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and may hold stock or stock options in Merck & Co., Inc., Rahway, NJ, USA. V116 was developed by Merck & Co., Inc., Rahway, NJ, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in—or a financial conflict with—the subject matter or materials discussed in this manuscript apart from those disclosed herewith.

: This article does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below